Axsome Therapeutics, Inc. (AXSM): M&A transaction — Axsome completes final closing of Sunosi acquisition from Jazz Pharmaceuticals on Nov 14, 2022

Axsome Therapeutics, Inc.

Final closing of ex-U.S. assets for Sunosi occurred Nov 14, 2022, satisfying closing conditions.
Initial U.S. closing had occurred on May 9, 2022, as previously reported.
Acquisition covers worldwide rights to Sunosi excluding 12 Asian markets (e.g., China, Korea, Japan).
Financial statements and pro forma information were previously filed on July 21, 2022.

item 2.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Axsome Therapeutics, Inc. completed an acquisition involving Jazz Pharmaceuticals plc (closed 2022-11-14).

Action: acquisition
Counterparty: Jazz Pharmaceuticals plc
Closing: 2022-11-14

Exact text from the filing

The final closing contemplated by the Purchase Agreement (i.e., the conveyance of the ex-U.S. assets) occurred on November 14, 2022

View on SEC.gov

Browse all m&a transactions →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-025086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.